Revenue: As of FY2026 Q2, the actual value is USD 0.<h3>Financial Results for Fiscal Second Quarter 2026</h3><ul><li>Revenue: HeartSciences reported no meaningful revenue for the fiscal second quarter of 2026.</li><li>Cash and Cash Equivalents: As of October 31, 2025, the company had approximately $2.0 million in cash and cash equivalents.</li><li>Shareholders’ Equity: The company reported $4.2 million in shareholders’ equity as of October 31, 2025.</li></ul><h3>Outlook / Guidance</h3><ul><li>HeartSciences is actively engaged in commercial discussions with several healthcare institutions and expects to announce key customer wins in the near term. The company plans to host an investor call early in the new year to demonstrate the MyoVista Insights software and provide additional details regarding its commercialization strategy and market opportunity. The submission of the MyoVista wavECG device to the FDA represents an important regulatory milestone for the company.</li></ul>

HeartSciences | 8-K: FY2026 Q2 Revenue: USD 0